With advances in technologies of genetic testing, increasing subsets of cancer patients are found to harbor germline mutations. While having knowledge of the germline mutations allows better risk management, it may also subject the patient and family members to discrimination.
A precision oncology symposium is being held in Hong Kong on March 20th to discuss genetic testing and its ethical aspects. Dr. Shu-Jen Chen, Chief Scientific Officer of ACT Genomics, will start off the symposium by explaining the current technologies of genetic testing and hereditary genes. Following Dr. Chen’s talk, other renowned experts in the field will discuss the oncological management of hereditary cancers, the current situations in Hong Kong, and the possible ways to protect individuals undergoing genetic testing from discrimination.